Tempest Therapeutics, Inc. (TPST) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Tempest Therapeutics, Inc. (TPST) trades at $1.02 with AI Score 26/100 (Grade F). Tempest Therapeutics Inc. is a clinical-stage oncology company focused on developing small molecule therapeutics for cancer treatment. Market cap: $16.3M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 5, 2026TPST stock analysis for 2026: Analysts have set a consensus price target of $11.00 for Tempest Therapeutics, Inc., suggesting 978.4% upside from the current price of $1.02. The AI MoonshotScore is 26/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
TPST: 3/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Tempest Therapeutics, Inc. (TPST) Healthcare & Pipeline Overview
Tempest Therapeutics Inc. is a clinical-stage biotechnology firm specializing in small molecule therapeutics for cancer, with a focus on dual antagonist and selective antagonist approaches. Their Phase 1 trials for TPST-1495 and TPST-1120 aim to address solid tumors, positioning them in the competitive oncology market.
What Is the Investment Thesis for TPST?
Tempest Therapeutics, with a market capitalization of $16.3M, presents a high-risk, high-reward investment opportunity in the biotechnology sector. The company's value hinges on the successful progression of its Phase 1 clinical trials for TPST-1495 and TPST-1120. Positive data from these trials could serve as a significant catalyst, attracting further investment and potential partnerships. However, the inherent risks associated with early-stage drug development, including clinical trial failures and regulatory hurdles, must be considered. The company's ability to secure additional funding to support its research and development efforts is also crucial for its long-term viability. The negative beta of -1.89 suggests the stock moves inversely to the market, potentially offering diversification benefits during market downturns, but also indicating company-specific risks outweighing broader market trends.
Based on FMP financials and quantitative analysis
TPST Key Highlights
Market capitalization of $16.3M reflects the company's early stage and potential for growth.
- Currently focused on Phase 1 clinical trials for TPST-1495 and TPST-1120, targeting solid tumors.
- Developing TREX-1, a novel approach to cancer immunotherapy, representing a potential future growth driver.
- No dividend yield, consistent with clinical-stage biotech companies focused on reinvesting earnings into research and development.
- Beta of -1.89 indicates the stock is significantly less correlated with the overall market, but also highlights company-specific risks.
Who Are TPST's Competitors?
TPST is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TPST's Key Strengths?
Novel drug candidates targeting unmet needs in oncology.
- Experienced management team with expertise in drug development.
- Strong intellectual property position.
- Focus on small molecule therapeutics, which have advantages in terms of manufacturing and delivery.
What Are TPST's Weaknesses?
Early-stage clinical development with high risk of failure.
- Limited financial resources compared to larger pharmaceutical companies.
- Reliance on the success of a few key programs.
- Small number of employees.
What Could Drive TPST Stock Higher?
TPST catalyst: Interim data readout from the Phase 1 trial of TPST-1495 in solid tumors (expected in Q4 2026).
- Interim data readout from the Phase 1 trial of TPST-1120 in solid tumors (expected in Q4 2026).
- Enrollment and progression of patients in the Phase 1 trials for TPST-1495 and TPST-1120.
- Development and preclinical studies for TREX-1 program.
What Are the Key Risks for TPST?
Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to achieve positive results in Phase 1 clinical trials.
- Delays in regulatory approvals.
- Competition from other companies developing cancer therapeutics.
- Dependence on securing additional funding to support research and development.
- High attrition rate in oncology drug development.
What Are the Growth Opportunities for TPST?
- Successful Phase 1 Trial Outcomes: Positive results from the ongoing Phase 1 clinical trials for TPST-1495 and TPST-1120 could significantly increase the company's valuation. These trials are evaluating the safety and efficacy of these drug candidates in patients with solid tumors. Positive data would not only validate the company's scientific approach but also attract potential partnerships and further investment, potentially unlocking a market opportunity valued in the billions, given the prevalence of solid tumors.
- Advancement to Phase 2 Clinical Trials: Progressing TPST-1495 and TPST-1120 to Phase 2 clinical trials would represent a major milestone for Tempest Therapeutics. Phase 2 trials involve larger patient populations and focus on assessing the efficacy of the drug candidates. Successful completion of Phase 2 trials would significantly de-risk the programs and increase the likelihood of regulatory approval, opening up a substantial market share in the oncology therapeutics market.
- Development of TREX-1 Program: Tempest's development of TREX-1, a key cellular enzyme that regulates the innate immune response in tumors, represents a novel approach to cancer immunotherapy. This program has the potential to address a significant unmet need in cancer treatment by enhancing the body's own immune system to fight cancer cells. Successful development of TREX-1 could position Tempest as a leader in the field of cancer immunotherapy, capturing a significant portion of the growing immunotherapy market.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions could provide Tempest with access to additional funding, expertise, and resources. These partnerships could accelerate the development of its pipeline programs and expand its market reach. Collaborations could also validate the company's technology and increase its visibility within the industry, potentially leading to a larger market share.
- Expansion of Pipeline: Expanding its pipeline with additional drug candidates targeting different cancer pathways could diversify Tempest's risk and increase its long-term growth potential. By developing a portfolio of therapeutic programs, Tempest can reduce its reliance on the success of any single program and increase its chances of bringing multiple cancer treatments to market. This expansion could involve in-licensing new technologies or developing its own proprietary programs, creating a more robust and valuable company.
What Are TPST's Competitive Advantages?
- Proprietary small molecule therapeutics targeting novel cancer pathways.
- Strong intellectual property protection for its drug candidates.
- Expertise in drug discovery and development in the oncology field.
What Does TPST Do?
Founded in 2011 and headquartered in Brisbane, California, Tempest Therapeutics Inc. is dedicated to the discovery and development of innovative small molecule therapeutics for the treatment of cancer. Originally a subsidiary of Inception Sciences, Inc., Tempest operates as a clinical-stage company, focusing on advancing its pipeline of novel drug candidates through clinical trials. The company's research is centered on modulating key pathways involved in tumor growth and immune evasion. Tempest's lead programs include TPST-1495, a dual antagonist of EP2 and EP4 receptors of prostaglandin E2, and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha (PPARα). Both TPST-1495 and TPST-1120 are currently in Phase 1 clinical trials, evaluating their safety and efficacy in patients with solid tumors. Additionally, Tempest is developing TREX-1, a key cellular enzyme that regulates the innate immune response in tumors, representing a novel approach to cancer immunotherapy. Tempest Therapeutics aims to address unmet medical needs in oncology by developing innovative therapies that can improve patient outcomes.
What Products and Services Does TPST Offer?
- Develop small molecule therapeutics for cancer treatment.
- Focus on modulating key pathways involved in tumor growth and immune evasion.
- Conduct Phase 1 clinical trials for TPST-1495 and TPST-1120.
- Target EP2 and EP4 receptors of prostaglandin E2 with TPST-1495.
- Target peroxisome proliferator-activated receptor alpha (PPARα) with TPST-1120.
- Develop TREX-1, a key cellular enzyme that regulates the innate immune response in tumors.
How Does TPST Make Money?
- Develop and license or sell novel cancer therapeutics.
- Generate revenue through partnerships and collaborations with larger pharmaceutical companies.
- Secure funding through venture capital and public offerings to support research and development.
What Industry Does TPST Operate In?
Tempest Therapeutics operates within the competitive biotechnology industry, specifically focusing on oncology. The market for cancer therapeutics is substantial and growing, driven by an aging population and advancements in cancer diagnostics. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying to develop innovative treatments. Tempest's focus on small molecule therapeutics and novel targets like EP2, EP4, and PPARα positions it within a niche segment of the oncology market. Success in this space requires significant investment in research and development, as well as the ability to navigate complex regulatory pathways.
Who Are TPST's Key Customers?
- Cancer patients in need of new treatment options.
- Oncologists and other healthcare professionals who treat cancer patients.
- Pharmaceutical companies seeking to expand their oncology portfolios.
Financial Health
Tempest Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Tempest Therapeutics, Inc. (TPST) Valuation Context
Valued at $16.3M, TPST is classified as a micro-cap stock. Relative to its peer group, TPST's quantitative score of 26/100 is below the peer average of 76/100.
Company Profile
Tempest Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Brisbane, US. The company is led by CEO Matthew Angel. TPST has traded publicly since 2012.
Earnings Track Record
Tempest Therapeutics, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 91.3% below estimates on average.
Forward Outlook
Wall Street analysts project Tempest Therapeutics, Inc. revenue of about $17.9M for fiscal 2026, with EPS near $-1.34.
TPST Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying activity suggests confidence in the company's future prospects, indicating that management believes in their growth strategy.
- Community sentiment has shifted positively as investors discuss potential breakthroughs in Tempest's therapeutic pipelines, especially in oncology.
- New partnerships and collaborations announced in the last month have generated excitement about the company's ability to expand its research capabilities and market reach.
- The overall market perception around biotech stocks has improved, with increased interest in innovative therapies, positioning Tempest favorably among its peers.
Bear Case
- Concerns about the slow pace of clinical trial results have led some investors to question the company's ability to deliver on its promises in a timely manner.
- Negative sentiment persists regarding the competitive landscape, with many investors highlighting the challenges Tempest faces against larger, more established companies.
- Recent discussions in the community have reflected skepticism about the company's funding status, raising fears about its ability to sustain operations without additional capital.
- Market volatility and broader economic uncertainties have made investors cautious, leading to a more bearish outlook on speculative biotech investments like Tempest.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TPST Latest News
-
12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga · Jul 8, 2026
-
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga · Jun 23, 2026
TPST Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TPST.
Price Targets
Consensus target: $11.00
TPST MoonshotScore
What does this score mean?
The MoonshotScore rates TPST 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Matthew Angel
CEO
Matthew Angel serves as the Chief Executive Officer of Tempest Therapeutics Inc. His background includes extensive experience in the biotechnology industry, with a focus on oncology drug development. Prior to joining Tempest, he held leadership positions at various biotech companies, where he was responsible for overseeing research and development programs, clinical trials, and regulatory submissions. His expertise spans across multiple therapeutic areas, including small molecule therapeutics and immunotherapy. He is responsible for managing 24 employees.
Track Record: Under Matthew Angel's leadership, Tempest Therapeutics has focused on advancing its pipeline of small molecule therapeutics through Phase 1 clinical trials. Key milestones include the initiation of clinical trials for TPST-1495 and TPST-1120, as well as the continued development of the TREX-1 program. His strategic decisions have been instrumental in securing funding and partnerships to support the company's research and development efforts.
What Investors Ask About Tempest Therapeutics, Inc. (TPST) — Healthcare
What does the AI Score mean for TPST?
TPST holds an AI Score of 26/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Tempest Therapeutics Inc. is a clinical-stage oncology company focused on developing small molecule therapeutics for cancer treatment. Their pipeline includes TPST-1495 and TPST-1120, both …
What does Tempest Therapeutics, Inc. do?
Tempest Therapeutics, Inc. is a clinical-stage oncology company focused on discovering, developing, and commercializing small molecule therapeutics to treat cancer. Its pipeline includes TPST-1495, a dual antagonist of EP2 and EP4 receptors, and TPST-1120, a selective antagonist of PPARα, both currently in Phase 1 clinical trials for solid tumors.
What do analysts say about TPST stock?
Given Tempest Therapeutics' early clinical stage, analyst coverage and consensus are limited. Valuation metrics are primarily driven by the potential success of its Phase 1 clinical trials for TPST-1495 and TPST-1120. Growth considerations hinge on positive data readouts, partnerships, and the ability to secure additional funding.
What are the main risks for TPST?
The primary risks for Tempest Therapeutics include the inherent uncertainties of clinical-stage drug development, particularly the possibility of clinical trial failures for TPST-1495 and TPST-1120. Regulatory hurdles and delays in obtaining FDA approval also pose significant risks. Competition from other companies developing cancer therapeutics, as well as the company's dependence on securing additional funding to support its research and development efforts, further contribute to the overall risk profile.
How does Tempest Therapeutics, Inc. navigate regulatory approval processes?
Tempest Therapeutics, Inc. is currently in the early stages of clinical development, focusing on Phase 1 trials. Their regulatory strategy involves close collaboration with regulatory agencies like the FDA to ensure compliance with guidelines and requirements. They are building a comprehensive data package to support future regulatory submissions.
How does Tempest Therapeutics, Inc. manage patent expiration risks?
As a clinical-stage company, Tempest Therapeutics, Inc. is focused on establishing a strong intellectual property portfolio around its drug candidates. This includes securing patents for the composition of matter, formulations, and methods of use.
What are the key factors to evaluate for TPST?
Tempest Therapeutics, Inc. (TPST) holds an AI score of 26/100 (low). Analysts target $11.00 (+978%). Tempest Therapeutics, with a market capitalization of $16.3M, presents a high-risk, high-reward investment opportunity in the biotechnology sector. Not financial advice.
How frequently does TPST data refresh on this page?
TPST's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TPST's recent stock price performance?
Tempest Therapeutics, Inc. (TPST) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel drug candidates targeting unmet needs in oncology. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited available data.
- Future clinical trial results may significantly impact the company's prospects.